Safety and Efficacy of Medical Cannabis in Fibromyalgia

0
97

BACKGROUND:

Chronic pain may
be
treated
by medical
cannabis
.
Yet,
there
is
scarce
evidence
to
support
the
role
of medical
cannabis
 in
the
treatment
of
fibromyalgia.
The
aim
of
the
study
was
to
investigate
the
characteristics,
safety,
and
effectiveness
of medical
cannabis
 therapy
for
fibromyalgia.

METHODS:

A
prospective
observational
study
with
six
months
follow-up
period
based
on
fibromyalgia
patients
who
were
willing
to
answer
questionnaire
in
a
specialized medical
cannabis
 clinic
between
2015
and
2017.

RESULTS:

Among
the
367
fibromyalgia
patients,
the
mean
age
was
52.9
±
15.1,
of
whom
301
(82.0%)
were
women.
Twenty
eight
patients
(7.6%)
stopped
the
treatment
prior
to
the
six
months
follow-up.
The
six
months
response
rate
was
70.8%. Pain intensity
(scale
0-10)
reduced
from
a
median
of
9.0
at
baseline
to
5.0
(p <
0.001),
and
194
patients
(81.1%)
achieved
treatment
response.
In
a
multivariate
analysis,
age
above
60
years
(odds
ratio
[OR] 0.34,
95%
C.I
0.16-0.72),
concerns
about cannabis treatment
(OR
0.36,
95%
C.I
0.16-0.80),
spasticity
(OR
2.26,
95%
C.I
1.08-4.72),
and
previous
use
of cannabis (OR
2.46
95%
C.I
1.06-5.74)
were
associated
with
treatment
outcome.
The
most
common
adverse
effects
were
mild
and
included
dizziness
(7.9%),
dry
mouth
(6.7%),
and
gastrointestinal
symptoms
(5.4%).

CONCLUSION:


Medical
cannabis
 appears
to
be
a
safe
and
effective
alternative
for
the
treatment
of
fibromyalgia
symptoms.
Standardization
of
treatment
compounds
and
regimens
are
required.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

eighteen − 6 =